CHPA pushes for DXM bill
This article was originally published in The Tan Sheet
The Consumer Healthcare Products Association "already has begun an initiative to seek reintroduction" of the Dextromethorphan Distribution Act of 2006 in the next session of Congress since the Senate did not address the legislation before Congress adjourned Dec. 9. The bill, which passed the House by voice vote Dec. 6, would allow FDA to limit the distribution of bulk ingredient DXM to people or entities registered with the agency, and would make it more difficult for teens to abuse the drug (1"The Tan Sheet" Dec. 11, 2006, p. 11). "We are committed to educating and empowering parents to take responsibility and action by informing their children of the dangers of abusing both Rx and OTC medicines," CHPA President Linda Suydam states in the association's executive newsletter Dec. 15...
You may also be interested in...
House leadership made a lame duck priority of legislation to restrict sales and distribution of bulk forms of dextromethorphan (DXM), but HR 5280 did not get the same treatment in the Senate
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.